WO1996022380A3 - Method to improve screening efficiency in fused cells - Google Patents

Method to improve screening efficiency in fused cells Download PDF

Info

Publication number
WO1996022380A3
WO1996022380A3 PCT/US1996/001169 US9601169W WO9622380A3 WO 1996022380 A3 WO1996022380 A3 WO 1996022380A3 US 9601169 W US9601169 W US 9601169W WO 9622380 A3 WO9622380 A3 WO 9622380A3
Authority
WO
WIPO (PCT)
Prior art keywords
fused cells
screening efficiency
improve screening
marker
cells
Prior art date
Application number
PCT/US1996/001169
Other languages
French (fr)
Other versions
WO1996022380A2 (en
Inventor
Aya Jakobovitz
Margaret C Hardy
Larry Green
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Priority to JP8522458A priority Critical patent/JPH10512449A/en
Priority to EP96905259A priority patent/EP0804604A2/en
Priority to AU49066/96A priority patent/AU4906696A/en
Publication of WO1996022380A2 publication Critical patent/WO1996022380A2/en
Publication of WO1996022380A3 publication Critical patent/WO1996022380A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method for improving the efficiency of screening fused cells for the presence of desired genes is disclosed. The method involves providing the desired gene with a marker that overcomes the sensitivity of an immortalizing cell fusion partner to certain medium conditions. The method is illustrated by the inclusion of a marker on immunoglobulin genes present in B cells.
PCT/US1996/001169 1995-01-20 1996-01-19 Method to improve screening efficiency in fused cells WO1996022380A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8522458A JPH10512449A (en) 1995-01-20 1996-01-19 Method for improving screening efficiency of fused cells
EP96905259A EP0804604A2 (en) 1995-01-20 1996-01-19 Method to improve screening efficiency in fused cells
AU49066/96A AU4906696A (en) 1995-01-20 1996-01-19 Method to improve screening efficiency in fused cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37627995A 1995-01-20 1995-01-20
US376,279 1995-01-20

Publications (2)

Publication Number Publication Date
WO1996022380A2 WO1996022380A2 (en) 1996-07-25
WO1996022380A3 true WO1996022380A3 (en) 1996-09-12

Family

ID=23484361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/001169 WO1996022380A2 (en) 1995-01-20 1996-01-19 Method to improve screening efficiency in fused cells

Country Status (6)

Country Link
EP (1) EP0804604A2 (en)
JP (1) JPH10512449A (en)
KR (1) KR19980701536A (en)
AU (1) AU4906696A (en)
CA (1) CA2210986A1 (en)
WO (1) WO1996022380A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573999B2 (en) 2005-12-07 2017-02-21 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
DK1212422T3 (en) 1999-08-24 2007-07-02 Medarex Inc Human CTLA-4 antibodies and their uses
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
CN1652820A (en) 2002-04-12 2005-08-10 梅达雷克斯公司 Methods of treatment using CTLA-4 antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0298807A1 (en) * 1987-06-19 1989-01-11 Transgene S.A. Method for the production of stable cell lines from transgenic animals for the production of specific proteins; tumour cell lines and proteins obtained
EP0459372A2 (en) * 1990-06-01 1991-12-04 Takeda Chemical Industries, Ltd. Hybridoma and production of biologically active substance
WO1994002602A1 (en) * 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0298807A1 (en) * 1987-06-19 1989-01-11 Transgene S.A. Method for the production of stable cell lines from transgenic animals for the production of specific proteins; tumour cell lines and proteins obtained
EP0459372A2 (en) * 1990-06-01 1991-12-04 Takeda Chemical Industries, Ltd. Hybridoma and production of biologically active substance
WO1994002602A1 (en) * 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NIKOLAS A. DORFMAN: "The optimal technological approach to the development of human hybridomas", JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, vol. 4, 1985, pages 213 - 239, XP002006320 *
R. THOMAS TAGGART ET AL.: "Stable antibody-producing murine hybridomas", SCIENCE, vol. 219, no. 4589, 11 March 1983 (1983-03-11), LANCASTER, PA US, pages 1228 - 1230, XP000573783 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573999B2 (en) 2005-12-07 2017-02-21 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens

Also Published As

Publication number Publication date
EP0804604A2 (en) 1997-11-05
KR19980701536A (en) 1998-05-15
AU4906696A (en) 1996-08-07
CA2210986A1 (en) 1996-07-25
WO1996022380A2 (en) 1996-07-25
JPH10512449A (en) 1998-12-02

Similar Documents

Publication Publication Date Title
DK1141371T3 (en) Methods for producing polypeptides in Aspergillus mutant cells
AU6837696A (en) Chimeric animal and method for constructing the same
AU5007885A (en) Somatic human hybridoma fusion partner for the production of human monoclonal antibodies
AU542303B2 (en) Antibody production by rat myeloma cells
DK1244808T3 (en) Method for screening multiple transformed cells using bicistronic expression of fluorescent proteins
AU8063798A (en) Secretory immunoglobulin produced by single cells and methods for making and using same
AUPP807899A0 (en) Codon utilization
AU4940096A (en) Host cell expressing reduced levels of a metalloprotease and methods using the host cell in protein production
WO1997017447A3 (en) Plant vde genes and methods related thereto
WO1996022380A3 (en) Method to improve screening efficiency in fused cells
WO2003064630A3 (en) Cell culture medium
AU5116596A (en) Cell culture method
GB2239315B (en) Mutant fungal strain detection
EP0357350A3 (en) Novel xanthene dyes
FI964208A (en) A method for controlling the precipitation of metallophosphate in fermentations with a high cell density
NO20015494L (en) Method of culturing cells
AU5148296A (en) Culture medium for insect cells
EP0148644A3 (en) A novel fusion partner and its products
NO20010246L (en) Process for producing proteins in transformed yeast cells
WO2000042203A3 (en) Methods for producing polypeptides in cyclohexadepsipeptide-deficient cells
AU2099800A (en) Production of proteins
CA2284133A1 (en) Novel cell line and screening method with the use of the same
WO1998050580A3 (en) Method for determining the number of transmuted copies in genetically manipulated cells
WO1998023747A3 (en) Isolated mammalian dendritic cell genes; related reagents
ES8600388A1 (en) Method for the cell fusion of laver.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP KR NO NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP KR NO NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2210986

Country of ref document: CA

Ref country code: CA

Ref document number: 2210986

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019970704927

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1996 522458

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996905259

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996905259

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970704927

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996905259

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019970704927

Country of ref document: KR